News - Brightlands Venture Partners

Matisse Pharmaceuticals about to start third dose level in a Phase I/IIa study with its lead compound M6229 in septic patients

September 09, 2022

Second orphan medicinal product designation for Neuro-Cells® paves way for application to both chronic and trauma-induced neurodegenerative diseases

September 08, 2022

Brightlands Venture Partners invests in AgTech company S+dB

September 07, 2022

Verdify increases seed round to €2.1 million for accelerated rollout of personalised recipe platform

July 01, 2022

Hy2Care receives € 6M EU funding for optimal cartilage repair

June 14, 2022

Stem cell biotech Neuroplast enrolls first patient in Phase II clinical trial of transformative Neuro-Cells® treatment for Traumatic Spinal Cord Injury

March 29, 2022

Mane Biotech raises € 1.7 million to further develop its regenerative medicine technology to combat hair loss

January 18, 2022

PectCof raises € 2 million for its innovative coffee pulp-based food ingredients

January 12, 2022

Verdify raises €1.3 million to scale its Swapmeals® platform for personalised recipes

December 13, 2021

Matisse Pharmaceuticals receives approval from the Dutch Health Authorities to initiate a Phase I study with lead compound M6229

November 22, 2021

Dutch stem cell biotech Neuroplast secures € 10 million in Series B funding

November 17, 2021

Vertoro raises funding to scale up its Goldilocks® liquid lignin technology

October 14, 2021

More information

If you have any questions or want to know more about us
Contact us